Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Immortelle (Helichrysum italicum) flower extract is used for liver and bile support, anti-inflammatory effects, and skin health. Clinical evidence is limited. Generally well tolerated. Contains flavonoids including naringenin and apigenin that inhibit CYP enzymes; potential interactions with drugs metabolised by CYP1A2, CYP2C9, and CYP3A4. Avoid high-dose use in pregnancy due to lack of safety data.
Biological and Chemical Classification
- Scientific Name
- Helichrysum italicum
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Immortelle Flower indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 აპრ 2026, 12:10
Evidence Distribution
-
Observational / other LOW evidence YELLOWChemical composition and bioactivity of supercritical CO(2) extracts of Helichrysum italicum, Helichrysum plicatum, Helichrysum sanguineum and Helichrysum stoechas. ↗Bahadirli NP et al.. Chemical composition and bioactivity of supercritical CO(2) extracts of Helichrysum italicum, Helichrysum plicatum, Helichrysum sanguineum and Helichrysum stoechas.. J Sci Food Agric. 2026. PMID:41771762.PMID 41771762 ↗Journal J Sci Food AgricYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41771762/
-
Observational / other LOW evidence YELLOWThe Influence of Phyto-Active Incorporated Topical Formulations on Cell Migration in Scratch Assays and In vivo Wound Model in Mice. ↗Yapar EA et al.. The Influence of Phyto-Active Incorporated Topical Formulations on Cell Migration in Scratch Assays and In vivo Wound Model in Mice.. Curr Drug Deliv. 2026. PMID:41540520.PMID 41540520 ↗Journal Curr Drug DelivYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41540520/
-
Observational / other LOW evidence YELLOWGap-free genome assembly and multiomics analysis of Helichrysum italicum reveal its genome evolution and the role of 4-Coumarate-CoA Ligase (4CL) in phenylpropanoid… ↗Luo J et al.. Gap-free genome assembly and multiomics analysis of Helichrysum italicum reveal its genome evolution and the role of 4-Coumarate-CoA Ligase (4CL) in phenylpropanoid biosynthesis.. Int J Biol Macromol. 2026. PMID:41308770.PMID 41308770 ↗Journal Int J Biol MacromolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41308770/
-
Observational / other LOW evidence YELLOWFirst EST-SSRs of Helichrysum italicum (Roth) G. Don (Asteraceae) Revealed Insights into the Genetic Diversity and Population Structure in Corsica. ↗Gabrovu0161ek P et al.. First EST-SSRs of Helichrysum italicum (Roth) G. Don (Asteraceae) Revealed Insights into the Genetic Diversity and Population Structure in Corsica.. Plants (Basel). 2025. PMID:41470676.PMID 41470676 ↗Journal Plants (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41470676/
-
Observational / other LOW evidence YELLOWGrowth performance, carcass characteristics and meat quality of quails fed diets containing Helichrysum italicum essential oil. ↗Kop Bozbay C et al.. Growth performance, carcass characteristics and meat quality of quails fed diets containing Helichrysum italicum essential oil.. Trop Anim Health Prod. 2025. PMID:41432770.PMID 41432770 ↗Journal Trop Anim Health ProdYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41432770/
-
Observational / other LOW evidence YELLOWSoil water-holding capacity does not mediate aridity effects on plant functional traits in Iberian dune ecosystems. ↗Moreira X et al.. Soil water-holding capacity does not mediate aridity effects on plant functional traits in Iberian dune ecosystems.. Ann Bot. 2025. PMID:40795458.PMID 40795458 ↗Journal Ann BotYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40795458/
-
Observational / other LOW evidence YELLOWPhenolic composition, cholinesterase inhibition, and in silico study of traditional medicinal plants from Bosnia And Herzegovina. ↗Ibragic S et al.. Phenolic composition, cholinesterase inhibition, and in silico study of traditional medicinal plants from Bosnia And Herzegovina.. Nat Prod Res. 2025. PMID:40753589.PMID 40753589 ↗Journal Nat Prod ResYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40753589/
-
Observational / other LOW evidence YELLOWNatural antitussive products for children and adolescents: darkness and shadow. ↗Ciprandi G et al.. Natural antitussive products for children and adolescents: darkness and shadow.. Minerva Pediatr (Torino). 2025. PMID:40512457.PMID 40512457 ↗Journal Minerva Pediatr (Torino)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40512457/
-
Observational / other LOW evidence YELLOWCan Provence Flora Offer Effective Alternatives to Widely Used Medicinal Plants? A Comparative Study of Antioxidant Activity and Chemical Composition Using Molecular… ↗Achard-Baccati C et al.. Can Provence Flora Offer Effective Alternatives to Widely Used Medicinal Plants? A Comparative Study of Antioxidant Activity and Chemical Composition Using Molecular Networking.. Molecules. 2025. PMID:40363877.PMID 40363877 ↗Journal MoleculesYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40363877/
-
Observational / other LOW evidence YELLOWThe Use of Plants That Seal Blood Vessels in Preparations Applied Topically to the Skin: A Review. ↗Roman BH et al.. The Use of Plants That Seal Blood Vessels in Preparations Applied Topically to the Skin: A Review.. Molecules. 2025. PMID:40363780.PMID 40363780 ↗Journal MoleculesYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40363780/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Immortelle Flower. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Immortelle Flower
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.